VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Executive Officer, Charles Rowland, will present a corporate overview of the Company at the 2016 BIO Investor Forum, taking place October 18-19 at the Westin St. Francis in San Francisco. The presentation will also be available via webcast at the link listed below.
Aurinia Presentation Details
Date: Tuesday, October 18th
Time: 4:30pm PT
Location: Westin St. Francis Hotel
Webcast: http://www.veracast.com/webcasts/bio/investorforum2016/28130277027.cfm
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The company is headquartered in Victoria, BC and focuses its development efforts globally.
Visit www.auriniapharma.com for more information.
